Linda Bain has been the Chief Financial Officer of Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, since 2015. Prior to joining Codiak, Ms. Bain was CFO at Adverum Biotechnologies, Inc. (previously Avalanche Biotechnologies, Inc.) and Vice President, Finance, Business Operations, and Treasurer at bluebird bio, Inc., where she played an instrumental role in the IPO for each company.
Ms. Bain has held senior roles at Genzyme Corporation, including Vice President of Finance, Global Manufacturing and Operations and Vice President of Finance of Genzyme Genetics, where she was a member of the team that divested the business unit to LabCorp for $925 million. Earlier in her career, she served in senior finance roles at Fidelity Investments and AstraZeneca Pharmaceuticals and as an auditor at Deloitte & Touche.
Ms. Bain also serves on the Board of Directors for Autolus Therapeutics plc and Arvinas, Inc., and Hemab Therapeutics. She received a Bachelor of Science in Accounting and Business Administration and an Honors degree in Accounting and Business Administration from the University of the Free State, located in South Africa.